McCune J M, Péault B, Streeter P R, Rabin L
New Enterprise Research Division, SyStemix, Inc., Palo Alto, CA 94303.
Immunol Rev. 1991 Dec;124:45-62. doi: 10.1111/j.1600-065x.1991.tb00615.x.
Work in the SCID-hu system has progressed significantly over the past 3-4 years. Reliable SCID-hu constructs can now be created for the evaluation of long-term multilineage human hematopoiesis, human immune function, and HIV infection of human hematolymphoid organs in vivo. Given these constructs, a variety of therapeutically important modalities can now be discovered and developed with a relevant in vivo model, prior to the time that they are moved into the clinic. With further progress in this and other preclinical models, useful therapies for important human disease states will hopefully be forthcoming at an even faster pace.
